Morgan, C. J, Page, E., Schaefer, C., Chatten, K., Manocha, A., Gulati, S., Curran, H. V, Brandner, B. & Leweke, FM. (2013). Cerebrospinal fluid anandamide levels, cannabis use and psychotic-like symptoms. British Journal of Psychiatry,202(5), 381-382. United Kingdom: Royal College of Psychiatrists. Retrieved from https://doi.org/10.1192/bjp.bp.112.121178
Anandamide is a ligand of the endocannabinoid system. Animals show a depletion following repeated Δ9-tetrahydrocannabinol (THC) administration but the effect of cannabis use on central nervous system levels of endocannabinoids has not been previously examined in humans. Cerebrospinal fluid (CSF) levels of the endocannabinoids anandamide, 2-arachidonoylglycerol (2-AG) and related lipids were tested in 33 volunteers (20 cannabis users). Lower levels of CSF anandamide and higher levels of 2-AG in serum were observed in frequent compared with infrequent cannabis users. Levels of CSF anandamide were negatively correlated with persisting psychotic symptoms when drug-free. Higher levels of anandamide are associated with a lower risk of psychotic symptoms following cannabis use.